The Claim
Among US veterans with pre-existing substance use disorders and type 2 diabetes, initiation of GLP-1 receptor agonists is associated with a 39% lower risk of drug overdose and a 25% lower risk of suicidal ideation or attempt over a three-year period compared to initiation of SGLT-2 inhibitors, suggesting potential benefits for critical safety outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For US veterans with type 2 diabetes and a history of substance use, starting a GLP-1 drug (like Ozempic) may lower their chances of overdosing on drugs or having suicidal thoughts compared to starting a different diabetes drug called an SGLT-2 inhibitor.
See the scientific wording
Among US veterans with pre-existing substance use disorders and type 2 diabetes, initiating GLP-1 receptor agonists is associated with a 39% lower risk of drug overdose and a 25% lower risk of suicidal ideation or attempt over three years compared to initiating SGLT-2 inhibitors, suggesting potential benefits for critical safety outcomes.
What the research says
1 studyThe study looked at veterans with diabetes and substance use issues and found that those who started GLP-1 drugs had fewer overdoses and suicidal thoughts than those who started other diabetes drugs, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.